Veery Capital’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$343K Hold
3,971
– – 0.09% 69
2026
Q2
$267K Sell
3,971
-82
-2% -$5.46K 0.07% 80
2026
Q1
$255K Buy
4,053
+5
+0.1% +$348 0.08% 75
2025
Q4
$269K Hold
4,048
– – 0.08% 74
2025
Q3
$272K Hold
4,048
– – 0.09% 71
2025
Q2
$353K Buy
4,048
+25
+0.6% +$1.96K 0.12% 52
2025
Q1
$275K Hold
4,023
– – 0.11% 64
2024
Q4
$313K Buy
4,023
+19
+0.5% +$1.41K 0.12% 59
2024
Q3
$268K Hold
4,004
– – 0.1% 72
2024
Q2
$454K Hold
4,004
– – 0.18% 57
2024
Q1
$555K Hold
4,004
– – 0.23% 47
2023
Q4
$497K Buy
4,004
+8
+0.2% +$817 0.22% 50
2023
Q3
$373K Sell
3,996
-12
-0.3% -$1.35K 0.18% 62
2023
Q2
$515K Sell
4,008
-260
-6% -$31.4K 0.24% 47
2023
Q1
$496K Hold
4,268
– – 0.26% 42
2022
Q4
$483K Hold
4,268
– – 0.29% 39
2022
Q3
$344K Hold
4,268
– – 0.22% 46
2022
Q2
$318K Hold
4,268
– – 0.2% 51
2022
Q1
$546K Hold
4,268
– – 0.3% 38
2021
Q4
$573K Hold
4,268
– – 0.3% 40
2021
Q3
$583K Hold
4,268
– – 0.33% 40
2021
Q2
$456K Hold
4,268
– – 0.27% 45
2021
Q1
$383K Sell
4,268
-184
-4% -$17.3K 0.24% 48
2020
Q4
$411K Buy
+4,452
New +$398K 0.28% 45

Other funds holding DXCM

Veery Capital's DXCM Position: Q3 2026 in Review

Veery Capital held its DexCom (DXCM) position steady in Q3 2026 at 3,971 shares worth $343K. The position accounts for 0.09% of the portfolio, ranked #69.

Veery Capital first reported a position in DXCM in Q4 2020 and has held it in 24 quarters since. The position peaked at $583K in Q3 2021. 205 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Veery Capital held 3,971 shares of DexCom worth $343K as of Q3 2026.
  • Veery Capital left its DexCom share count unchanged in Q3 2026.
  • DexCom made up 0.09% of Veery Capital's portfolio in Q3 2026, its #69 holding.
  • Veery Capital first reported a position in DexCom in Q4 2020 and has held it in 24 quarters since.
  • Veery Capital's DexCom position peaked at $583K in Q3 2021.
  • 205 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Veery Capital's 13F filing for Q3 2026, filed 7 Oct 2026.